Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Clearmind Medicine Inc. CMND NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
35/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Clearmind Medicine Inc. (CMND) is a Biotechnology company in the Healthcare sector, currently trading at $0.65. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: CMND trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Net income is $4M (loss), growing at +18.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $1M equity (Debt-to-Equity (D/E) ratio 1.49, moderate). Current ratio is 1.22 (adequate). Debt-to-assets is 29.2%. Total assets: $6M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 80/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

CMND SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 80/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CMND

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
80/100
CMND: +0%/yr revenue is, +18.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet CMND: Debt-to-Equity (D/E) ratio 1.49 (moderate), Current ratio is 1.22 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
CMND: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.595-52.4
Volume2.14M
Avg Volume (30D)607.21K
Market Cap$88.83K
Beta (1Y)-1.03
Share Statistics
EPS (TTM)-30.34
Shares Outstanding$127.09K
IPO Date2022-11-15
Employees4
CEOAdi Zuloff-Shani
Financial Highlights & Ratios
Gross Profit$-49.36K
EBITDA$-3.72M
Net Income$-3.86M
Operating Income$-5.67M
Total Cash$5.58M
Total Debt$1.78M
Net Debt$-2.14M
Total Assets$6.08M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryCA
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA1850535016

Price Chart

Track all markets on TradingView
CMND
Clearmind Medicine Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.60 52WK RANGE 52.40

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$10.04
+1.93%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.97
+0.43%
 NBY
NBY
NovaBay Pharmaceuticals, Inc.
$1.88
-3.59%
 COEP
COEP
Coeptis Therapeutics, Inc.
$12.99
+4.42%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 REVB
REVB
Revelation Biosciences, Inc.
$1.26
+5.00%
 HILS
HILS
Hillstream BioPharma, Inc.
$0.24
+5.66%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message